Leuprolide
Also known as Lupron, Eligard, Leuprorelin
A GnRH agonist suppressing testosterone and estrogen production, approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
Regulatory Pathway
Dosing Protocol
Typical Dose
7.5 mg monthly depot (common)
Frequency
Daily, monthly, or every 3-6 months
Duration
Months to years depending on indication
Timing & Administration
Administer via Intramuscular or subcutaneous depot injection. Frequency: Daily, monthly, or every 3-6 months.
Popular Uses
Mechanism of Action
Initially stimulates then suppresses gonadotropin release through continuous GnRH receptor stimulation, resulting in reversible medical castration following initial flare.
Research Summary
Evidence level: fda approved. Clinical status: FDA Approved - Multiple indications.
Side Effects & Safety
Important Warnings
- Tumor flare reaction on initiation
References
No references available.
Related Peptides
Browse all →A naturally occurring peptide hormone essential for social bonding, childbirth, and lactation. Under investigation for autism, anxiety, and social disorders.
View profileA synthetic version of gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive conditions.
View profileSynthetic vasopressin analog that selectively activates V2 receptors in kidneys, promoting water reabsorption.
View profile